Literature DB >> 2070707

Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases.

W Kimura1, A Kuroda, Y Morioka.   

Abstract

A clinicopathological analysis of endocrine tumors of the pancreas, using 800 autopsy cases (422 men, 378 women, mean age 78.7) was accomplished. The results were: (1) Endocrine tumors and similar lesions were found in 3% or 24 cases (25 lesions). Twenty lesions (20 cases) were found to be tumors and five lesions (five cases) were determined to be hyperplasia of Langerhans islets. (2) Incidence of tumor was 10% (6/60) in individuals having histological studies of all sections of the pancreas, and 1.6% (12/738) in individuals having histological studies of three random sections of the pancreas. (3) None of the cases with tumors and hyperplastic lesions showed symptoms of hormone production. (4) Immunohistochemical analysis revealed hormone production in all 20 tumor cases and multiple hormone production was found in 14 of these (70%). (5) Ductular or tubular structures were found in or adjacent to the tumors in 12 cases (60%) and hyperplasia in one case (20%). Langerhans islets, 500 microns or larger in size, were found in three lesions of the tumor (15%). Langerhans islets with the mean diameter of normal islets + 2 SD or larger also were found around five tumors (25%) and three hyperplasias (60%). The above findings suggest that endocrine tumors of the pancreas are prevalent and that they do not produce symptoms of excessive hormone production even though they do continue to produce hormones. Some of the endocrine tumors or hyperplasias develop from totipotent stem cells of the duct epithelia, and factors promoting the growth of Langerhans islets might exist.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2070707     DOI: 10.1007/BF01297144

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  26 in total

1.  Hyperinsulinism secondary to disease of the pancreas and organs adjacent to the pancreas: a review of the world literature.

Authors:  E O FRIEDLANDER
Journal:  Ann Intern Med       Date:  1960-04       Impact factor: 25.391

2.  Tumors of the pancreatic islets.

Authors:  J SIERACKI; R B MARSHALL; R C HORN
Journal:  Cancer       Date:  1960 Mar-Apr       Impact factor: 6.860

3.  Islet cell carcinoma of the pancreas.

Authors:  A L Cubilla; S I Hajdu
Journal:  Arch Pathol       Date:  1975-04

4.  Adenomas of the Islands of Langerhans.

Authors:  S Warren
Journal:  Am J Pathol       Date:  1926-07       Impact factor: 4.307

5.  Pancreatic islet cell carcinoma. I. Clinical features of 52 patients.

Authors:  L E Broder; S K Carter
Journal:  Ann Intern Med       Date:  1973-07       Impact factor: 25.391

6.  Epidemiology of pancreatic cancer in Connecticut.

Authors:  R E Moldow; R R Connelly
Journal:  Gastroenterology       Date:  1968-12       Impact factor: 22.682

7.  Pseudoneoplastic proliferation of endocrine cells in pancreatic fibrosis.

Authors:  S A Bartow; K Mukai; J Rosai
Journal:  Cancer       Date:  1981-06-01       Impact factor: 6.860

8.  Pancreatic polypeptide in insulinomas, gastrinomas, vipomas, and glucagonomas.

Authors:  J M Polak; S R Bloom; T E Adrian; P Heitz; M G Bryant; A G Pearse
Journal:  Lancet       Date:  1976-02-14       Impact factor: 79.321

9.  Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material.

Authors:  L Grimelius; G T Hultquist; B Stenkvist
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1975

10.  Pathomorphologic, biochemical, and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome).

Authors:  W Creutzfeldt; R Arnold; C Creutzfeldt; N S Track
Journal:  Hum Pathol       Date:  1975-01       Impact factor: 3.466

View more
  64 in total

1.  Diagnosis of pancreatic neuroendocrine tumors and the role of endoscopic ultrasound.

Authors:  Linda S Lee
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

2.  A small glucagonoma of the pancreas with evident ductular and tubular structures.

Authors:  K Morikane; W Kimura; S Inoue; T Muto
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

Review 3.  Genetics of pancreatic neuroendocrine tumors: implications for the clinic.

Authors:  Antonio Pea; Ralph H Hruban; Laura D Wood
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-28       Impact factor: 3.869

4.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 5.  [Classification of gastro-entero-pancreatic neuroendocrine tumors].

Authors:  A Perren; A Schmitt; P Komminoth; M Pavel
Journal:  Radiologe       Date:  2009-03       Impact factor: 0.635

6.  Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

Authors:  Jens Juul Holst
Journal:  Diabetologia       Date:  2013-07-03       Impact factor: 10.122

7.  Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.

Authors:  S Bonner-Weir; P A In't Veld; G C Weir
Journal:  Diabetes Obes Metab       Date:  2014-01-29       Impact factor: 6.577

Review 8.  Diagnosis and management of insulinoma.

Authors:  Takehiro Okabayashi; Yasuo Shima; Tatsuaki Sumiyoshi; Akihito Kozuki; Satoshi Ito; Yasuhiro Ogawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 9.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

10.  Malignant insulinoma causing liver metastasis 8 years after the initial surgery: report of a case.

Authors:  N Sata; W Kimura; T Kanazawa; T Muto
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.